CD19 CAR-T Therapy for Patients With B-cell Non-Hodgkin's Lymphoma

Status Recruiting

Clinical Trial Summary

A Study of CD19 CAR-T Therapy for Patients With B-cell Non-Hodgkin's Lymphoma.

Clinical Trial Description

This is a single arm, open-label, single-center study. This study is indicated for patients with CD19+ non-Hodgkin's lymphoma. The selections of dose levels and the number of subjects are based on clinical trials of similar foreign products. 36 patients will be enrolled. Primary objective is to explore the safety, main consideration is dose-related safety. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04661020
Study type	Interventional
Source	Zhejiang University
Contact	He Huang, PhD
Phone	86-13605714822
Email	hehuangyu@126.com
Status	Recruiting
Phase	Phase 2
Start date	December 3, 2020
Completion date	December 20, 2026

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05050461` - Immune Response After SARS-CoV-2 Vaccination in a Context of Non-Hodgkin Lymphoma	N/A
Recruiting	`NCT06160362` - The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL)	N/A
Recruiting	`NCT04435743` - Efficacy and Safety of Lenalidomide With or Without Rituximab and Other Drugs in B-cell Non-Hodgkin's Lymphomas
Recruiting	`NCT03720496` - Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCART Cell Therapy	Phase 1
Recruiting	`NCT06346912` - CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL	Early Phase 1
Recruiting	`NCT05518383` - B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021	Phase 4
Recruiting	`NCT02081937` - CART-19 Immunotherapy in Mantle Cell Lymphoma	Phase 1/Phase 2
Recruiting	`NCT06321289` - Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL	Phase 1/Phase 2
Not yet recruiting	`NCT05909059` - CAR T-cell Therapy in Patients With Renal Dysfunction	Phase 2
Recruiting	`NCT05631912` - TRAC Locus-inserted CD19-targeting STAR-T Cell Therapy in r/r B-NHL	Phase 1/Phase 2
Completed	`NCT04094142` - Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma	Phase 2
Recruiting	`NCT05143112` - Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Lymphoma	Phase 1/Phase 2
Recruiting	`NCT03497533` - Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19	Phase 1/Phase 2
Recruiting	`NCT04532268` - A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL	Early Phase 1
Terminated	`NCT03488251` - PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma	Phase 2
Recruiting	`NCT05741359` - The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma	Phase 1
Recruiting	`NCT04897477` - Azacytidine, Bendamustine, Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's Lymphoma	Phase 1/Phase 2
Recruiting	`NCT06156774` - SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project